---

10 July 2007 : Column 1436W—continued

10 July 2007 : Column 1437W

10 July 2007 : Column 1438W

10 July 2007 : Column 1439W

10 July 2007 : Column 1440W

TA#	Condition and drugs appraised	Referral date	Publication	Recommendation
3	ovarian cancer—paclitaxel (Taxol)	4 November 1999	May 2000	Selective
6	breast cancer—docetaxel (Taxotere), paclitaxel (Taxol)	4 November 1999	June 2000	Selective
23	recurrent malignant glioma—temozolomide (Temodal)	12 July 2000	April 2001	Selective
25	pancreatic cancer gemcitabine (Gemzar)	12 July 2000	May 2001	Selective
26	lung cancer (non-small cell)—paclitaxel (Taxol), docetaxel (Taxotere), gemcitabine (Gemzar), vinorelbine (Navelbine)	12 July 2000	June 2001	Routine
28	ovarian cancer (advanced)—topetecan (Hycamtin)	12 July 2000	August 2001	Selective
29	chronic lymphocytic leukaemia—fludarabine (Fludara)	12 July 2000	September 2001	Routine
30	breast cancer—docetaxel (Taxotere), paclitaxel (Taxol)	Review of TA06 12 July 2000	September 2001	Selective
33	colorectal cancer (advanced)—irinotecan (Campto), oxaliplatin (Eloxatin), raltitrexed (Tomudex)	12 July 2000	March 2002	Selective
34	breast cancer (advanced)—tratuzumab (Herceptin)	12 July 2000	March 2002	Selective
37	non-Hodgkin's lymphoma—rituximab (MabThera)	12 July 2000	March 2002	Selective
45	ovarian cancer—pegylated liposomal doxorubicin hydrochloride (Caelyx)	12 March 2001	July 2002	Selective
50	chronic myeloid leukaemia—imatinib (Glivec)	12 March 2001	September 2002	Routine
54	breast cancer (advanced)—vinorelbine (Navelbine)	12 July 2000	December 2002	Selective
55	ovarian cancer—paclitaxel (Taxol)	Review of TA03 12 July 2000	January 2003	Routine
61	colorectal cancer (Metastatic)—capecitabine (Xeloda), tegafur with uracil (Uftoral)	31 July 2001	May 2003	Routine
62	breast cancer (locally advanced)—capecitabine (Xeloda)	31 July 2001	May 2003	Routine
65	aggressive non-Hodgkin's lymphoma—rituximab (MabThera)	20 May 2002	September 2003	Selective
70	chronic myeloid leukaemia—imatinib (Glivec)	Review of TA50 20 May 2002	October 2003	Selective
86	gastro-intestinal stromal tumours (GIST)—imatinib (Glivec)	31 March 2003	October 2004	Selective
91	ovarian cancer (advanced)—paclitaxel (Taxol), pegylated liposomal doxorubicin hydrochloride (Caelyx), topotecan (Hycamtin)	Review of TA28, TA45 and TA55	May 2005	Selective
93	colorectal cancer (advanced)—irinotecan (Campto), oxaliplatin (Eloxatin), raltitrexed (Tomudex)	Review of TA33 1 April 2005	August 2005	Selective
100	colon cancer (adjuvant)—oxaliplatin (Eloxatin), capecitabine (Xeloda)	21 June 2004	April 2006	Routine
101	prostate cancer (hormone refractory)—docetaxel (Taxotere)	21 June 2004	June 2006	Routine
107	breast cancer (early)—trastuzumab (Herceptin)	21 July 2005 (transferred to STA programme November 2005). Licence granted for use in early breast cancer May 2006	August 2006	Selective
108	breast cancer (early)—paclitaxel (Taxol)	5 April 2005 (transferred to STA programme November 2005)	September 2006	Not recommended
109	breast cancer (early)—docetaxel (Taxotere)	5 April 2005 (transferred to STA programme November 2005)	September 2006	Routine
110	follicular lymphoma—rituximab (MabThera)	5 April 2005 (transferred to STA programme November 2005)	September 2006	Routine
112	breast cancer (early)—anastrozole (Arimidex), exemestane (Aromasin), letrozole (Femara)	21 June 2004	November 2006	Routine
116	metastatic breast cancer—gemcitabine (Gemzar)	5 April 2005 (transferred to STA programme November 2005)	January 2007	Selective
118	metastatic colorectal cancer—bevacizumab (Avastin) and cetuximab (Erbitux)	21 June 2004	January 2007	Not recommended
119	chronic lymphocytic leukaemia—fludarabine (Fludara)	Review of TA29 5 April 2005 (transferred to STA programme November 2005. Deferred July 2006 awaiting Medical Research Council trial)	February 2007	Not recommended
121	glioma (newly diagnosed and high grade)—carmustine implants (Gliadel) and temozolomide (Temodal)	21 June 2004	June 2007	Selective

There are also a number of appraisals of cancer drugs on NICE's work programme on which guidance has not yet been issued. The following table lists all the technology appraisals relating to cancer treatments, including the date of referral, the condition and the drugs appraised, whether they are being appraised as a Single Technology Appraisal (STA) or Multiple Technology Appraisal (MTA), the status of the appraisal and where available the expected date of issue.

10 July 2007 : Column 1441W

10 July 2007 : Column 1442W

STA/MTA	Condition and drugs appraised	Referral date	Status	Expected date of issue
STA	breast cancer (advanced or metastatic)—lapatinib (Tyverb)	19 December 2006	—	TBC
STA	colon cancer (adjuvant)—irinotecan (Campto)	16 June 2004 (transferred to STA programme August 2006)	Suspended: Campto is not currently licensed in the United Kingdom for this indication.	TBC
STA	non-Hodgkin's lymphoma—rituximab (MabThera)	Review of TA37 5 April 2005	—	December 2007
STA	glioblastoma multiforme (recurrent)—carmustine implants (Gliadel)	21 June 2004 (transferred to STA programme August 2006)	—	January 2008
STA	head and neck cancer—cetuximab (Erbitux)	21 June 2004	Three appeals have been made against the Final Appraisal Determination.	To be confirmed—subject to outcome of appeals.
STA	lung cancer (non small cell)—bevacizumab (Avastin)	19 December 2006	—	January 2008
STA	lung cancer (non small cell)—erlotinib (Tarceva)	5 April 2005 (transferred to STA programme November 2005)	NICE awaits the decision of the appeal hearing heard on 6 June 2007.	To be confirmed—subject to outcome of appeals.
STA	lung cancer (non small cell)—pemetrexed (Alimta)	5 April 2005 (transferred to STA programme November 2005)	NICE awaits the decision of the appeal hearing heard on 6 June 2007.	To be confirmed—subject to outcome of appeals.
MTA	lung cancer (non small cell)—gefitinib (Iressa)	1 April 2003	Suspended: Iressa is not currently licensed in the UK for this indication.	To be confirmed
MTA	mesothelioma—pemetrexed disodium	21 June 2004	—	September 2007
STA	relapsed multiple myeloma—bortezomib (Velcade)	21 July 2005 (transferred to STA programme November 2005)	—	To be confirmed
STA	pancreatic cancer—Rubetican	21 June 2004 (transferred to STA programme November 2005)	Suspended: The manufacturers have withdrawn their licence application.	To be confirmed
STA	prostate cancer (hormone refractory)—Atrasentan	21 June 2004 (transferred to STA programme November 2005)	Suspended: Atrasentan is not currently licensed in the UK for this indication.	To be confirmed
STA	breast cancer—bevacizumab (Avastin)	19 June 2007	—	To be confirmed
MTA	renal cell carcinoma—bevacizumab (Avastin), sorafenib tosylate (Nexavar) and sunitinib (Sutent)	19 June 2007	—	To be confirmed

---